SGO 2026 Annual Meeting on Women’s Cancer

Genomic and Transcriptomic Analysis To Uncover Potential Biomarkers of Response and Primary Resistance to Mirvetuximab Soravtansine in Patients with Ovarian Cancer

The authors utilized Lens to investigate genomic and transcriptomic alterations that may drive response or primary resistance to Mirvetuximab soravtansine (MIRV), a first-in-class folate receptor alpha targeted antibody-drug conjugate. Their findings suggest that upregulation of JAK1 and MAPK1 pathways may contribute to primary resistance to MIRV through enhanced survival and proliferation signaling and that increased ABCC1 expression may also reduce payload efficacy.

MUC16 in ovarian cancer: high, stable expression across histologic subtypes, disease stages, and platinum sensitivity status supports antibody-drug conjugate development

In collaboration with Whitehawk therapeutics, the authors sought to assess MUC16 expression in a large population, across diverse histologic subtypes and stages of ovarian cancer. RNA sequencing data from Tempus were used to examine MUC16 expression. MUC16 showed tumor-selective protein enrichment and mRNA–protein concordance, and expression was stable across most histologic subtypes, disease stages, and irrespective of platinum sensitivity.

High and stable MUC16 expression in endometrial cancer highlights potential for targeted antibody-drug conjugate development

This study examined MUC16 expression across endometrial cancer subtypes and stages in a large cohort. Tempus xR data was used to assess MUC16 expression across histologic subtypes, stages, and primary vs metastatic endometrial tumors. MUC16 expression varied across endometrial cancer subtypes and was most highly expressed in serous adenocarcinoma and endometrioid adenocarcinoma. In serous adenocarcinoma, MUC16 expression was uniformly high irrespective of disease stage and showed the highest expression of known ADC targets in development.

MUC16 As a Therapeutic Target: Advancing Antibody-Drug Conjugates for Ovarian Cancer Treatment

The aims of this study were to quantify MUC16 RNA expression across ovarian cancer histologic subtypes and in platinum-refractory/resistant ovarian cancer (PROC) versus PSOC high-grade serous carcinoma, and to compare MUC16 expression with that of other therapeutic targets in late-stage development. The authors found that MUC16 mRNA expression was substantially higher than that of genes encoding other ADC targets that are in late-stage development for ovarian cancer. In high-grade serous ovarian carcinoma, MUC16 expression remained high irrespective of platinum-sensitivity status. In high-grade serous ovarian carcinoma, MUC16 defines an independent population, as suggested by the weak correlations in mRNA expression between MUC16 and FOLR1 (FRα), ERBB2 (HER2), VTCN1 (B7-H4), CDH6, CLDN6, and PTK7. This population may benefit from MUC16-targeted therapy due to uniquely high MUC16 expression.

Group 9: Targeted Tactics and Therapies